Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Oaktree Acquisition Corp. III Life Sciences
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-91.6% vs price
Base Case (Median)
-83.9% vs price
Bull Case (75th pct.)
-76.2% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.07 | -99.3% | High (40%) |
| PE Comparable | $3.39 | -68.5% | Medium (25%) |
Based on 2 out of 8 methods, OACC appears overvalued at the current price of $10.76. The base case fair value of $1.73 implies 83.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.